Fax: (011) 81-823-21-0478
Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non–small cell lung cancer
Version of Record online: 18 JAN 2013
Copyright © 2013 American Cancer Society
Volume 119, Issue 4, pages 792–798, 15 February 2013
How to Cite
Harada, H., Miyamoto, K., Yamashita, Y., Nakano, K., Taniyama, K., Miyata, Y., Ohdan, H. and Okada, M. (2013), Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non–small cell lung cancer. Cancer, 119: 792–798. doi: 10.1002/cncr.27754
- Issue online: 4 FEB 2013
- Version of Record online: 18 JAN 2013
- Manuscript Accepted: 21 JUN 2012
- Manuscript Revised: 18 MAY 2012
- Manuscript Received: 20 FEB 2012
- non–small cell lung cancer
Even after early detection and curative resection of early stage non–small cell lung cancer (NSCLC), a significant fraction of patients develop recurrent disease. Molecular biomarkers that can predict the risk of recurrence thus need to be identified to improve clinical outcomes.
Using the methylation-specific polymerase chain reaction assay, promoter methylation of the breast cancer susceptibility gene 1 (BRCA1) was assessed in cancer tissues from 70 patients with curatively resected stage I NSCLC. The clinical relevance of BRCA1 methylation status was evaluated in terms of outcome of the disease.
Methylation of the BRCA1 promoter was detected in 13 of 70 patients (18.6%). Multiple logistic regression analysis revealed that BRCA1 methylation was an independent risk factor for recurrence (P = .0197) and that patients with BRCA1 methylation demonstrated significantly poorer recurrence-free survival compared to those without (P = .0139). Cox's proportional hazard regression analysis revealed that BRCA1 methylation was an independent risk factor for recurrence-free survival (P = .0155).
Methylated BRCA1 can be a potential biomarker that predicts the prognosis after curative resection of stage I NSCLC. Considering that BRCA1 plays a role in chemotherapy-induced apoptosis, it is plausible that identification of methylated BRCA1 could provide information that is clinically relevant to tailored adjuvant therapy. Cancer 2013. © 2013 American Cancer Society.